Assistant Professor, Radiation Oncology, Washington University School of Medicine
Radiation Oncology
Dr. Julie K. Schwarz, MD
|
|
Give Review
Dr. Julie K. Schwarz works in the field of Radiation Oncology. She studied medicine at Washington University School of Medicine in St. Louis. She over the years received 1 awards: "CMS Meaningful Use Stage 1 Certification". Doctor Julie K. Schwarz, MD is a published MD. She has 28 publications published. The most current publication "Clinical implementation of multisequence MRI-based adaptive intracavitary brachytherapy for cervix cancer."
Publications
- Intensity modulated radiation therapy for recurrent ovarian Cancer refractory to chemotherapy.
- Brachytherapy Is Associated With Improved Survival in Inoperable Stage I Endometrial Adenocarcinoma: A Population-Based Analysis.
- BRAF mutation is not predictive of long-term outcome in papillary thyroid carcinoma.
- Cervical Gross Tumor Volume Dose Predicts Local Control Using Magnetic Resonance Imaging/Diffusion-Weighted Imaging-Guided High-Dose-Rate and Positron Emission Tomogra...
- Concomitant chemotherapy and radiation for the treatment of advanced-stage endometrial Cancer.
- Treatment Approach, Surveillance and Outcome of Well-differentiated Thyroid Cancer in Childhood and Adolescence.
- Postradiation Damage to the Pelvic Girdle in Cervical Cancer Patients: Is Intensity-Modulated Radiation Therapy Safer Than Conventional Radiation?
- 2012 MICHAEL FRY AWARD LECTURE: Translating Imaging Results into Tumor Biology: FDG-PET and The Response to Chemoradiation in Human Cervical Carcinoma.
- In vitro chemoresponse to cisplatin and outcomes in cervical Cancer.
- Tumor volume and subvolume concordance between FDG-PET/CT and diffusion-weighted MRI for squamous cell carcinoma of the cervix.
- Improve definition of titanium tandems in MR-guided high dose rate brachytherapy for cervical Cancer using proton density weighted MRI.
- Pathway-specific analysis of gene expression data identifies the PI3K/Akt pathway as a novel therapeutic target in cervical Cancer.
- Metabolic Response on Posttherapy FDG-PET Predicts Patterns of Failure After Radiotherapy for Cervical Cancer.
- Split-Field Helical Tomotherapy With or Without Chemotherapy for Definitive Treatment of Cervical Cancer.
- Prospective Phase I-II Trial of Helical Tomotherapy with or Without Chemotherapy for Postoperative Cervical Cancer Patients.
- Prognostic Utility of Squamous Cell Carcinoma Antigen in Carcinoma of the Cervix: Association with Pre- and Posttreatment FDG-PET.
- A microRNA expression signature for cervical Cancer prognosis.
- A miR-200 microRNA cluster as prognostic marker in advanced ovarian Cancer.
- The role of 18F-FDG PET in assessing therapy response in Cancer of the cervix and ovaries.
- 18-F-fluorodeoxyglucose-positron emission tomography evaluation of early metabolic response during radiation therapy for cervical Cancer.
- Tumor response and survival predicted by post-therapy FDG-PET/CT in anal Cancer.
- Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma.
- Comparison of molecular markers of hypoxia and imaging with (60)Cu-ATSM in Cancer of the uterine cervix.
- Regulation of the Chk2 protein kinase by oligomerization-mediated cis- and trans-phosphorylation.
- Outpatient-based high-dose-rate interstitial brachytherapy for gynecologic malignancies.
- AKT Inhibitors Promote Cell Death in Cervical Cancer through Disruption of mTOR Signaling and Glucose Uptake.
- Clinical implementation of multisequence MRI-based adaptive intracavitary brachytherapy for cervix Cancer.
Schools
Washington Center School of Medicine
Conditions Treated
- Vulvar Cancer
Doctors Specialties
- Radiation Oncology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Washington University -
Washington University - Barnes-Jewish Hospital -
Washington University School of Medicine in St. Louis
Hospital
-
Barnes-Jewish Hospital
Drug Facts
| NPI NUMBER | 1871634261 | |
| NPPES Provider LastName | SCHWARZ | |
| NPPES Provider FirstName | JULIE | |
| NPPES Provider ZIPCode | 631101032 | |
| NPPES Provider State | MO | |
| Specialty Description | Radiation Oncology | |
| Total Claim Count | 37.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1871634261 |
| Last Name Of The Provider | SCHWARZ |
| First Name Of The Provider | JULIE |
| View All |
Similar Doctors
|
Dr. Mackenzie D. Daly, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Douglas A. Miller, MD |
|
|
Dr. Frederick R. Zivnuska, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hsiu-San Lin, MD |
|
|
Dr. Benjamin W. Fischer-Valuck, MD |
|
|
Dr. Andrew J. Hope, MD |
|
|
Dr. Adam A. Garsa, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Audrey Wallace, MD |
|
|
Dr. Pawel T. Dyk, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael C. Roach, MD |
|
|
Dr. Sana Rehman, MD
This Doctor is OpenDoctor Recommended.
|